KROS Q1 2025 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$211M+254413.3% YoY

Gross Profit

$211M100.0% margin

Operating Income

$152M72.0% margin

Net Income

$148M70.3% margin

EPS (Diluted)

$3.62

QoQ Revenue Growth

+6844.3%

Cash Flow

Operating Cash Flow

$161M

Free Cash Flow

$161M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$785M

Total Liabilities

$56M

Stockholders' Equity

$729M

Cash & Equivalents

$721M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$211M	$83,000	+254413.3%
Gross Profit	$211M	$83,000	+254413.3%
Operating Income	$152M	-$48M	+413.6%
Net Income	$148M	-$43M	+444.3%

Revenue Segments

License

$195M92%

Service, Other

$16M8%